Xueying Zhou

Dr. Xueying Zhou


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2025 in Animals
Verified
Journal Article
Open access
PDF file
JWJianzhong Wang
Jianzhong Wang
XZXueying Zhou
Xueying Zhou
Sara T. ElazabSara T. Elazab
Sara T. Elazab
JHJian Huang
Jian Huang
WHWalter Hsu
Walter Hsu
Monoclonal antibody therapy has been a cornerstone of human healthcare for nearly four decades, effectively treating a wide range of diseases including cancers, autoimmune disorders, and inflammatory conditions. However, its application in veterinary medicine is a relatively recent development, offering a promising therapeutic approach for managing chronic diseases in small animals. Dogs and cats, like humans, suffer from chronic conditions such as cancer, arthritis, allergies, and chronic pain, which mAb therapy could potentially address. This review aims to explore the therapeutic potential of mAb therapy in small animal medicine, focusing on currently authorized products, including their mechanisms of action, clinical efficacy, and safety concerns. A comprehensive review of the literature was conducted to evaluate the use of mAbs in veterinary medicine, specifically in the treatment of chronic disorders. While mAb therapy has shown significant benefits in human healthcare, challenges remain in its application to veterinary practice, including safety concerns and the limited availability of approved products. Despite these challenges, mAb therapy holds great promise for improving the management of chronic diseases in animals, with future research and development potentially expanding its clinical use.

Verified
Journal Article
Open access
PDF file
TATalgat Assabayev
Talgat Assabayev
JHJinge Han
Jinge Han
HBHalihaxi Bahetijiang
Halihaxi Bahetijiang
VAVenera Abdrassilova
Venera Abdrassilova
MKMuhammad Asfandyar Khan
Muhammad Asfandyar Khan
BHBo Han
Bo Han
Nocardia cyriacigeorgica causes bovine mastitis, reduces milk quantity and quality, and is often resistant to antimicrobials. Selenomethionine (SeMet) is a form of selenium, which reduces reactive oxygen species (ROS)-mediated apoptosis and intramammary infections. However, the protective effects of SeMet on N. cyriacigeorgica-infected bovine mammary epithelial cells (bMECs) are unclear. The objective of this study was to evaluate whether SeMet mitigated N. cyriacigeorgica-induced inflammatory injury, oxidative damage and apoptosis in bMECs. Cells were cultured with or without being pretreated with 40 µM of SeMet for 12 h, then challenged with N. cyriacigeorgica (multiplicity of infection = 5:1) for 6 h. Although N. cyriacigeorgica was resistant to lincomycin, erythromycin, enrofloxacin, penicillin, amoxicillin, cephalonium, cephalexin, and ceftriaxone, 40 μM SeMet increased cell viability and inhibited lactate dehydrogenase release in infected bMECs. Furthermore, N. cyriacigeorgica significantly induced mRNA production and protein expression of TNF-α, IL-1β, IL-6, and IL-8 at 6 h. Cell membrane rupture, cristae degeneration and mitochondria swelling were evident with transmission electron microscopy. Superoxide dismutase (SOD) and glutathione peroxidase (GSH-px) activities were down-regulated after 3, 6, or 12 h, whereas malondialdehyde (MDA) and ROS contents were significantly upregulated, with cell damage and apoptosis rapidly evident (the latter increased significantly in a time-dependent manner). In contrast, bMECs pretreated with 40 μM SeMet before infection, SOD, and GSH-px activities were upregulated (p < 0.05); MDA and ROS concentrations were downregulated (p < 0.05), and apoptosis was reduced (p < 0.05). In conclusion, 40 μM SeMet alleviated inflammation, oxidative stress and apoptosis induced by N. cyriacigeorgica in bMECs cultured in vitro.

3 April 2023 in Antibiotics
Verified
Journal Article
Open access
PDF file
JWJianzhong Wang
Jianzhong Wang
XZXueying Zhou
Xueying Zhou
Sara T. ElazabSara T. Elazab
Sara T. Elazab
Seung-Chun ParkSeung-Chun Park
Seung-Chun Park
WHWalter Hsu
Walter Hsu
Macrolide antibiotics are important drugs to combat infections. The pharmacokinetics (PK) of these drugs are essential for the determination of their optimal dose regimens, which affect antimicrobial pharmacodynamics and treatment success. For most drugs, the measurement of their concentrations in plasma/serum is the surrogate for drug concentrations in target tissues for therapy. However, for macrolides, simple reliance on total or free drug concentrations in serum/plasma might be misleading. The macrolide antibiotic concentrations of serum/plasma, interstitial fluid (ISF), and target tissue itself usually yield very different PK results. In fact, the PK of a macrolide antibiotic based on serum/plasma concentrations alone is not an ideal predictor for the in vivo efficacy against respiratory pathogens. Instead, the PK based on drug concentrations at the site of infection or ISF provide much more clinically relevant information than serum/plasma concentrations. This review aims to summarize and compare/discuss the use of drug concentrations of serum/plasma, airway ISF, and tissues for computing the PK of macrolides. A better understanding of the PK of macrolide antibiotics based on airway ISF concentrations will help optimize the antibacterial dose regimen as well as minimizing toxicity and the emergence of drug resistance in clinical practice.

4 April 2025 in Frontiers in Veterinary Science
Verified
Journal Article
Open access
PDF file
LZLing Zhu
Ling Zhu
JHJinge Han
Jinge Han
HBHalihaxi Bahetijiang
Halihaxi Bahetijiang
GLGang Liu
Gang Liu
JKJohn P. Kastelic
John P. Kastelic
BHBo Han
Bo Han
Information regarding canine hypothyroidism in China remains limited, particularly regarding the redox status of affected dogs. Therefore, the objective of this study was to evaluate the redox status of dogs with hypothyroidism and observe how it changed after levothyroxine replacement therapy. A total of 10 healthy dogs (control group) and 10 dogs with hypothyroidism (treatment group) from China Agricultural University Veterinary Teaching Hospital were included in the study. The redox status was assessed in all 20 dogs. Thyroid profiles such as thyroxine (T4), free thyroxine (fT4), and thyroid-stimulating hormone (TSH) and biomarkers of oxidative stress, including superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-px), and malondialdehyde (MDA), were assessed on day 0 in all dogs and on days 14 and 45 post-levothyroxine sodium treatment in dogs with hypothyroidism. Dogs with hypothyroidism had decreased levels of serum T4 and fT4 and increased levels of serum TSH. Based on SOD, CAT, GSH-px, and MDA, dogs with hypothyroidism had oxidative stress. Following 45-day treatment with levothyroxine sodium (0.02 mg/kg orally twice daily), antioxidant parameters improved progressively: SOD increased from 60.2 to 76.7 U/mL (Day 0-14) and further to 83.3 U/mL (Day 45); CAT from 105.9 to 115.5 mU/mL (Day 0-14) reaching 132.9 mU/mL (Day 45); GSH-Px from 10.2 to 8.4 U/mL (Day 0-14) then 9.7 U/mL (Day 45), while MDA decreased from 8.2→6.8→4.4 μmol/L correspondingly. In conclusion, increased serum TSH and MDA concentrations, in addition to decreased serum T4 and fT4 concentrations and decreased SOD and CAT activities, indicated that there was oxidative stress in dogs with hypothyroidism. However, there were significant improvements in the redox status of biomarkers in the serum of dogs with hypothyroidism after treatment with levothyroxine sodium (0.02 mg/kg twice daily) for 45 days.

9 September 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
TATalgat Assabayev
Talgat Assabayev
JHJinge Han
Jinge Han
HBHalihaxi Bahetijiang
Halihaxi Bahetijiang
VAVenera Abdrassilova
Venera Abdrassilova
MKMuhammad Asfandyar Khan
Muhammad Asfandyar Khan
BHBo Han
Bo Han
Nocardia cyriacigeorgica causes bovine mastitis, reduces milk quantity and quality, and is often re-sistant to antimicrobials. Selenomethionine (SeMet) is a form of selenium, an essential trace el-ement. Although SeMet reduced ROS-mediated apoptosis and intramammary infections. How-ever, protective effects of SeMet on N. cyriacigeorgica-infected bovine mammary epithelial cells (bMECs) are unclear. The objective was to evaluate whether SeMet mitigated N. cyriacigeorgi-ca-induced inflammatory injury, oxidative damage and apoptosis in bMECs. Cells were cultured with or without being pretreated 40 µM of SeMet for 12 h, then challenged N. cyriacigeorgica (MOI=5:1) for 6 h. Although N. cyriacigeorgica was resistant to lincomycin, erythromycin, en-rofloxacin, penicillin, amoxicillin, cephalonium, cephalexin, and ceftriaxone, 40 μM SeMet in-creased cell viability and inhibited LDH release in infected bMECs. Furthermore, N. cyriacigeor-gica significantly induced mRNA production and protein expression of TNF-α, IL-1β, IL-6, and IL-8 at 6 h. Cell membrane rupture, cristae degeneration and mitochondria swelling were evi-dent with transmission electron microscopy. SOD and GSH-px activities were down regulated after 3, 6 or 12 h, whereas MDA and ROS contents were significantly upregulated, with cell damage and apoptosis rapidly evident (the latter increased significantly in a time-dependent manner). In contrast, bMECs pretreated with 40 μM SeMet before infection, SOD and GSH-px ac-tivities were upregulated (P < 0.05), MDA and ROS concentrations were downregulated (P < 0.05), and apoptosis was reduced (P < 0.05). In conclusion, 40 μM SeMet alleviated inflammation, oxi-dative stress and apoptosis induced by N. cyriacigeorgica in bMECs cultured in vitro.

12 January 2026 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
PDF file
MXMaolin Xu
Maolin Xu
TWTian Wang
Tian Wang
XDXian Deng
Xian Deng
YLYuxin Liu
Yuxin Liu
ZZZimeng Zhu
Zimeng Zhu
BHBo Han
Bo Han
Background: Mycoplasma bovis mastitis is an important disease of dairy cows; however, there are no commercial M. bovis vaccines and antimicrobial resistance is increasing. Furthermore, M. bovis lacks a cell wall and relies on host-derived cholesterol for survival and growth. Methods: We evaluated effects of fenofibrate, a peroxisome proliferator-activated receptor α (PPARα) agonist, on M. bovis infection, using both bovine mammary epithelial cells and a murine mastitis model. In vitro analyses assessed autophagy, nuclear Transcription Factor EB (TFEB) and Transcription Factor E3 (TFE3) translocation, cholesterol metabolism, and bacterial localization, whereas in vivo evaluations included inflammatory responses, lysosomal/autophagy protein expression, cholesterol content, and bacterial burden. Results: Fenofibrate enhanced autophagic flux via upregulation of LC3B and LAMP2, promoted nuclear translocation of TFEB and TFE3, and reduced intracellular cholesterol by repressing 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase (HMGCR) and Sterol Regulatory Element-Binding Transcription Factor 2 (SREBF2) while increasing Acetyl-Coenzyme A Acetyltransferase 1 (ACAT1) expression. Based on confocal imaging, fenofibrate disrupted co-localization between M. bovis and free cholesterol while enhancing its uptake by autophagosomes. In a murine mastitis model, fenofibrate alleviated inflammatory cell infiltration and cytokine release, restored lysosomal and autophagy protein expression, reduced cholesterol content, and significantly lowered bacterial burden. Conclusion: Fenofibrate enhanced defense capability of mammary epithelial cells against M. bovis infection through a dual mechanism—promoting autophagy and regulating cholesterol homeostasis—thereby reducing bacterial survival and protecting tissues from damage. This discovery provides a novel strategy for prevention and treatment of M. bovis infection, warranting further investigation in bovine models to assess pharmacokinetics, dosage, and clinical efficacy.